Adaptix, IBEX Partner on Point-of-Care Bone Scans
The two companies plan to integrate IBEX's CorteX bone health software into Adaptix's portable Ortho350 imaging system.
Updated on Nov. 19, 2026 in Healthcare

Adaptix Ltd. and IBEX Innovations Ltd. signed a Memorandum of Understanding to integrate IBEX's CorteX bone health software into Adaptix's Ortho350 imaging platform. The companies aim to offer bone density assessment at the point of care on a pay-per-scan basis.
Why it matters
The partnership seeks to make bone density assessment more widely available outside traditional settings. CorteX is not yet cleared for sale in the US, so its commercial availability there remains pending regulatory review.
The Ortho350 is FDA 510(k) cleared and CE marked, while CorteX is CE-marked with its FDA 510(k) submission still pending. Pricing and launch timing for the combined pay-per-scan service were not disclosed.
The players
Adaptix Ltd.
Adaptix Ltd. is a medical imaging company that develops the portable Ortho350 Digital Tomosynthesis system.
IBEX Innovations Ltd.
IBEX Innovations Ltd. is a company that develops the CorteX bone health software, which produces DXA-equivalent clinical biomarkers.
The details
Adaptix asked IBEX to join its exhibition stand at RSNA 2026 in Chicago, where the companies plan to showcase the integration. Preliminary surveys indicated patients would strongly welcome bone density assessment offered on a cash-pay basis.
Timeline
November 17, 2026: Adaptix and IBEX signed the Memorandum of Understanding.
RSNA 2026: Adaptix exhibits with IBEX at its stand in Chicago, Stand 3159.
Industry Position
The integration places CorteX's DXA-equivalent biomarkers onto a portable tomosynthesis system rather than a dedicated densitometer. This follows the broader move toward decentralized, point-of-care imaging in bone health.
Patients could eventually obtain a bone density report at the point of care on a pay-per-scan basis rather than at a dedicated densitometry facility. CorteX is not yet available for sale or use in the US, so access there is not currently possible.
The takeaway
Bone density screening may become easier to access if portable imaging and software integrations reach routine clinical use. Readers should watch for FDA clearance of CorteX before expecting availability in the US.
Further reading
For more on the industry behind this partnership, see Healthcare.
Source note: This article includes information reported by Imaging Technology News.



